Wedbush Expects Reduced Earnings for Stoke Therapeutics

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at Wedbush reduced their FY2025 earnings per share estimates for Stoke Therapeutics in a note issued to investors on Wednesday, November 5th. Wedbush analyst L. Chico now expects that the company will earn $0.12 per share for the year, down from their previous forecast of $0.35. Wedbush has a “Outperform” rating and a $32.00 price objective on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q4 2025 earnings at ($0.73) EPS, Q1 2026 earnings at ($0.71) EPS, Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at ($0.73) EPS, FY2026 earnings at ($2.88) EPS, FY2027 earnings at ($3.20) EPS, FY2028 earnings at ($2.94) EPS and FY2029 earnings at $0.96 EPS.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The business had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.

Other equities analysts also recently issued reports about the stock. Needham & Company LLC upped their price objective on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a report on Friday, October 10th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Stoke Therapeutics in a report on Wednesday, October 8th. Jefferies Financial Group began coverage on shares of Stoke Therapeutics in a research note on Friday, July 18th. They issued a “buy” rating and a $30.00 price target on the stock. BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Finally, JPMorgan Chase & Co. boosted their price objective on Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a report on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Stoke Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $31.00.

Stoke Therapeutics Trading Up 1.7%

STOK opened at $22.86 on Friday. The stock’s fifty day simple moving average is $26.47 and its 200 day simple moving average is $17.17. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $38.69. The stock has a market cap of $1.31 billion, a PE ratio of 34.12 and a beta of 1.32.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its holdings in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares during the period. Strs Ohio bought a new stake in Stoke Therapeutics during the third quarter worth about $150,000. Osaic Holdings Inc. grew its stake in Stoke Therapeutics by 263.3% during the second quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock worth $85,000 after buying an additional 5,427 shares in the last quarter. Finally, State of Wyoming bought a new position in Stoke Therapeutics in the 3rd quarter valued at about $184,000.

Insider Buying and Selling

In other news, insider Barry Ticho sold 5,931 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $25.72, for a total transaction of $152,545.32. Following the transaction, the insider directly owned 7,195 shares of the company’s stock, valued at approximately $185,055.40. This trade represents a 45.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 45,996 shares of Stoke Therapeutics stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $20.13, for a total transaction of $925,899.48. Following the completion of the sale, the director owned 91,585 shares of the company’s stock, valued at approximately $1,843,606.05. The trade was a 33.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 186,607 shares of company stock valued at $4,224,210. 9.50% of the stock is owned by company insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.